"Notably, with the downturn of the equity markets, this is only a modest premium to the highs of Biotie in summer 2015 and backing out net cash of $46 million from Biotie, this is only $317 million for a late-stage phase III drug that has a reasonable chance of working."
Michael Yee, analyst at RBC Capital Markets, on Biotie Therapies' acquisition by Acorda Therapeutics Inc. for $363 million
"The approval is a breakthrough for Samsung Bioepis because it's the start of their business into the global biosimilar competition. Samsung Bioepis is the second South Korean player in the market, and they'll have two or three more products coming into this market over the next year."
Jaechul Park, a biotech analyst at Mirae Asset Financial Group
"The fall is not caused by any particular incident – it's rather a systematic risk which could happen any day – and the sector is dragged down by the overall situation. We still expect China's pharmaceutical sector to grow at 10 to 20 percent over the year, which is higher than the GDP growth rate."
David Li, assistant vice president for health care research at Bocom International, on the Chinese stock market's free fall